NASDAQ | VICL: 3.07  +0.00
Home

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on our patented DNA delivery technologies and other therapeutic approaches.

View all news
RECENT NEWS
September 26, 2016
Vical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes
September 19, 2016
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
EVENTS & PRESENTATIONS
September 12, 2016
 Rodman & Renshaw 18th Annual Global Investment Conference
August 9, 2016
 Vical Inc. 2Q16 Financial Results Conference Call

PRODUCT PIPELINE

CONNECT WITH US

© 2016 Vical Inc.
P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
Powered By Q4 Web Systems 4.1.3.41
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.